A recent phase I/II clinical trial with HER2-CAR T cells (with CD28 signaling domain) in patients with recurrent/refractory HER2+ sarcoma demonstrated CAR-T cell persistence for 6 weeks without evident toxicities [14]. The gene discussed is ERBB2; the disease is sarcoma.